Cargando…

A real‐world data of Immune checkpoint inhibitors in solid tumors from India

BACKGROUND: Checkpoint inhibitors (Nivolumab and Pembrolizumab) are approved for multiple indications in solid tumors. However access to these therapies is limited in low and middle income countries. Hence we performed an audit to identify accessibility, adverse event rates, compliance, progression...

Descripción completa

Detalles Bibliográficos
Autores principales:	Noronha, Vanita, Abraham, George, Patil, Vijay, Joshi, Amit, Menon, Nandini, Mahajan, Abhishek, Janu, Amit, Jain, Srushti, Talreja, Vikas T, Kapoor, Akhil, Kumar Singh, Gunjesh, Khaddar, Satvik, Gupta, Kushal, Rathinasamy, Narmadha, Srinivas, Sujay, Agrawal, Amit, Ventrapati, Pradeep, Prabhash, Kumar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7940210/ https://www.ncbi.nlm.nih.gov/pubmed/33591635 http://dx.doi.org/10.1002/cam4.3617

Ejemplares similares

Prognostic Impact of Baseline Liver Metastasis in ALK Fusion-Positive Metastatic Lung Cancer: A Retrospective Review
por: Khaddar, Satvik, et al.
Publicado: (2022)

Real-World Experience of Patients with Inoperable, Stage III Non-small-Cell Lung Cancer Treated with Durvalumab after Chemoradiotherapy: Indian Experience
por: Noronha, Vanita, et al.
Publicado: (2020)

Concomitant use of antibiotics and immune checkpoint inhibitors in patients with solid neoplasms: retrospective data from real-world settings
por: Kapoor, Akhil, et al.
Publicado: (2020)

Association of Immune-Related Adverse Effects and Survival in Solid Tumor Patients Treated with PD1 Inhibitors
por: Kapoor, Akhil, et al.
Publicado: (2022)

Long-Term Outcomes of Crizotinib Treated ALK-Positive Lung Cancer Patients: A Retrospective Audit of Prospective Data from Resource-Constrained Settings
por: Kapoor, Akhil, et al.
Publicado: (2022)

An observational study to evaluate factors predicting survival in patients of non-small cell lung cancer with poor performance status in resource-constrained settings
por: Kapoor, Akhil, et al.
Publicado: (2021)

ALK-positive advanced non-small cell lung cancer patients with poor performance status: Outcomes in a real-world scenario
por: Singh, Ajaykumar, et al.
Publicado: (2022)

Phase III Non-inferiority Study Evaluating Efficacy and Safety of Low Dose Gemcitabine Compared to Standard Dose Gemcitabine With Platinum in Advanced Squamous Lung Cancer
por: Patil, Vijay, et al.
Publicado: (2019)

Third-line therapy in the epidermal growth factor receptor mutation-positive advanced nonsmall-cell lung cancer
por: Noronha, Vanita, et al.
Publicado: (2020)

Clinical Profile, Practice Pattern, and Outcomes With First-Line Therapy in ALK-Positive Lung Cancer: Real-World Data From Resource-Constrained Settings
por: Kapoor, Akhil, et al.
Publicado: (2022)

An exceptional response to nivolumab in relapsed and refractory malignant mesothelioma
por: Talreja, Vikas T., et al.
Publicado: (2019)

Use of lorlatinib subsequent to crizotinib in anaplastic lymphoma kinase-positive non-small cell lung cancer: Indian experience
por: Talreja, Vikas T., et al.
Publicado: (2019)

Exceptional response to oral metronomic chemotherapy in a rare case of sinonasal mucosal melanoma
por: Karn, Anukul, et al.
Publicado: (2021)

Leptomeningeal metastasis from non-small cell lung cancer— a post-hoc analysis from four randomised clinical trials
por: Patil, Vijay, et al.
Publicado: (2022)

EGFR mutation in squamous cell carcinoma of the lung: does it carry the same connotation as in adenocarcinomas?
por: Joshi, Amit, et al.
Publicado: (2017)

Diclofenac versus tramadol for mucositis related pain in head and neck cancer patients undergoing concurrent chemoradiation—a phase 3 study
por: Joshi, Amit, et al.
Publicado: (2021)

An exceptional response to olaparib in relapsed and refractory BRCA2 mutated non-small cell lung cancer in hereditary breast–ovarian cancer syndrome
por: Talreja, Vikas T., et al.
Publicado: (2020)

Systemic therapy for limited stage small cell lung carcinoma
por: Noronha, Vanita, et al.
Publicado: (2020)

Immune checkpoint inhibitors in patients with solid tumors and poor performance status: A prospective data from the real-world settings
por: Kapoor, Akhil, et al.
Publicado: (2021)

Lorlatinib in anaplastic lymphoma kinase-positive non-small cell lung cancer: Indian experience
por: Talreja, Vikas T., et al.
Publicado: (2020)

Neoadjuvant chemotherapy in a rare type of very locally advanced sinonasal carcinomas – long-term results from a tertiary care centre
por: Saha, Saswata, et al.
Publicado: (2023)

Small cell carcinoma of the oesophagus: experience of an Indian Tertiary Cancer Centre
por: Panda, Goutam Santosh, et al.
Publicado: (2022)

ROS1 mutation non-small cell lung cancer—access to optimal treatment and outcomes
por: Joshi, Amit, et al.
Publicado: (2019)

Lymphopenia during chemoradiation—foe or friend
por: Patil, Vijay M, et al.
Publicado: (2020)

Characteristics and clinical outcomes of pulmonary sarcomatoid carcinoma: experience from Tata Memorial Centre
por: Bondili, Suresh Kumar, et al.
Publicado: (2022)

Maintenance pemetrexed in nonsmall cell lung carcinoma: Outcome analysis from a tertiary care center
por: Pandey, Avinash Vijaykumar, et al.
Publicado: (2015)

Safety and efficacy of bevacizumab biosimilar in recurrent/ progressive glioblastoma
por: Kumar, Gunjesh, et al.
Publicado: (2021)

Exploring the implications of modified advanced lung cancer inflammation index on outcomes in patients with advanced non-small cell lung cancer
por: Mahajan, Abhishek, et al.
Publicado: (2023)

Impact of exon 19 versus exon 21 EGFR-activating mutation on outcomes with upfront pemetrexed–carboplatin chemotherapy
por: Noronha, Vanita, et al.
Publicado: (2017)

Efficacy of gefitinib in epidermal growth factor receptor-activating mutation-positive nonsmall cell lung cancer: Does exon 19 deletion differ from exon 21 mutation?
por: Joshi, Amit, et al.
Publicado: (2018)

Efficacy of Second-Line Pemetrexed-Carboplatin in EGFR-Activating Mutation-Positive NSCLC: Does Exon 19 Deletion Differ from Exon 21 Mutation?
por: Joshi, Amit, et al.
Publicado: (2017)

Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma
por: Patil, Vijay Maruti, et al.
Publicado: (2017)

Confusion worse confounded
por: Noronha, Vanita, et al.
Publicado: (2013)

Palliative chemotherapy in carcinoma nasopharynx
por: Patil, Vijay M., et al.
Publicado: (2019)

Study of Treatment Outcome in Adults with TFE-Related RCC
por: Singh, Ajaykumar Chandrabhan, et al.
Publicado: (2021)

Translation and Validation of COST - FACIT (Version 2) Questionnaire into Hindi and Marathi to Assess Financial Toxicity in Indian Cancer Patients
por: Joshi, Amit, et al.
Publicado: (2022)

The Importance of Brain Metastasis in EGFR Mutation Positive NSCLC Patients
por: Noronha, Vanita, et al.
Publicado: (2014)

ALK Positive Lung Cancer: Clinical Profile, Practice and Outcomes in a Developing Country
por: Noronha, Vanita, et al.
Publicado: (2016)

Thyroid cancer in Gardner’s syndrome: Case report and review of literature
por: Punatar, Sachin B, et al.
Publicado: (2012)

Geriatric oncology: The need of the hour
por: Joshi, Amit, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_7i4pdipi805m8eos4f6b2jbiv4